
|Articles|February 15, 2003
Foresighted
Novartis Ophthalmics and Valley Forge Pharmaceuticals Inc. have entered into a licensing agreement for a novel eye medication for myopia, which in phase II clinical trials reduced progression of the disease by 50% in the first 12 months of therapy.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves veligrotug-vvze (Lumvoa) for thyroid eye disease across active and chronic stages
2
Detecting peripheral retinal lesions in children with myopia
3
FDA grants priority review to Satralizumab sBLA for thyroid eye disease
4
4DMT completes enrollment in 4FRONT-2, global phase 3 trial of 4D-150 in wet AMD
5



























